MY157582A - Medical composition containing rebamipipe - Google Patents

Medical composition containing rebamipipe

Info

Publication number
MY157582A
MY157582A MYPI2010000374A MYPI20100374A MY157582A MY 157582 A MY157582 A MY 157582A MY PI2010000374 A MYPI2010000374 A MY PI2010000374A MY PI20100374 A MYPI20100374 A MY PI20100374A MY 157582 A MY157582 A MY 157582A
Authority
MY
Malaysia
Prior art keywords
medical composition
salt
rebamipipe
composition containing
present
Prior art date
Application number
MYPI2010000374A
Inventor
Yoshio Hara
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MY157582A publication Critical patent/MY157582A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

THE PRESENT INVENTION PROVIDES A PHARMACEUTICAL PREPARATION WHEREIN THE EXPRESSION OF BITTERNESS IS REDUCED. THE MEDICAL COMPOSITION OF THE PRESENT INVENTION CONTAINS REBAMIPIDE OR A SALT THEREOF AND L-ARGININE OR A SALT THEREOF. THE PREFERABLE EMBODIMENT OF THE MEDICAL COMPOSITION OF THE PRESENT INVENTION CONTAINS REBAMIPIDE OR A SALT THEREOF AND L-ARGININE OR A SALT THEREOF ALONG WITH AT LEAST ONE SWEETENER SELECTED FROM THE GROUP CONSISTING OF THAUMATIN, STEVIA AND LUOHAN FRUIT EXTRACTS. BY ADDING SUCH A SWEETENER, BITTERNESS OF MEDICAL COMPOSITION ATTRIBUTABLE TO REBAMIPIDE OR A SALT THEREOF CAN BE REMARKABLY REDUCED.
MYPI2010000374A 2007-08-10 2008-08-05 Medical composition containing rebamipipe MY157582A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007209284 2007-08-10

Publications (1)

Publication Number Publication Date
MY157582A true MY157582A (en) 2016-06-30

Family

ID=39884986

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010000374A MY157582A (en) 2007-08-10 2008-08-05 Medical composition containing rebamipipe

Country Status (7)

Country Link
JP (2) JP5328789B2 (en)
KR (1) KR101551506B1 (en)
CN (1) CN101778626B (en)
AR (1) AR067887A1 (en)
MY (1) MY157582A (en)
TW (1) TW200918060A (en)
WO (1) WO2009022674A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012232062B2 (en) * 2011-03-24 2017-04-20 Otsuka Pharmaceutical Co., Ltd. A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide
JP5756727B2 (en) * 2011-09-30 2015-07-29 ハウス食品グループ本社株式会社 Granule
WO2014021637A1 (en) * 2012-07-31 2014-02-06 가톨릭대학교 산학협력단 Composition comprising rebamipide as active ingredient for preventing or treating hyperlipemia and diseases associated therewith
CN104883895B (en) * 2012-12-28 2017-12-29 花王株式会社 Beverage containing di-coffee mesitoyl quinine acid
JP6468919B2 (en) * 2014-03-31 2019-02-13 富士フイルム富山化学株式会社 Granular solid formulation containing cephalosporin ester
KR20170039347A (en) * 2015-10-01 2017-04-11 삼진제약주식회사 Novel opthalmic composition comprising rebamipide and method for preparing the same
US20170295834A1 (en) * 2015-11-25 2017-10-19 Alexander LaCroix All-Natural Bitterness-Reducing Flavor System
CN110167551B (en) 2016-12-28 2022-06-14 富士胶片富山化学株式会社 Pharmaceutical composition
JP7011300B2 (en) * 2017-12-19 2022-02-10 株式会社島田製薬 HMBCa-containing granule manufacturing method and supplements
KR101923519B1 (en) * 2018-06-26 2019-02-27 대우제약 주식회사 A water-soluble, multi-use eyedrops composition for the treatment of dry eye syndrome containing rebamipide and a method for solubilization and stabilization thereof
KR20230090185A (en) 2021-12-14 2023-06-21 메디케어제약 주식회사 Pharmaceutical composite formulation for treating rheumatoid arthritis with gastric mucosal lesion
KR20230090184A (en) 2021-12-14 2023-06-21 메디케어제약 주식회사 Pharmaceutical composite formulation comprising esomeprazole and rebamipide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420832T2 (en) * 1993-10-21 2000-01-13 Otsuka Pharma Co Ltd The use of carbostyril derivatives in the manufacture of a medicament for inhibiting the production of interleukin-8
JPH10306038A (en) * 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd Bromhexine-containing solution
JP3466921B2 (en) * 1998-06-03 2003-11-17 大塚製薬株式会社 Taste masking pharmaceutical formulation
JP3417857B2 (en) * 1998-12-11 2003-06-16 日清オイリオ株式会社 seasoning
KR20040104020A (en) * 2003-06-02 2004-12-10 진양제약주식회사 A new rebamipide lysinate, rebamipide argininate and pharmaceutical preparation containing the same as active substance
JP4244715B2 (en) * 2003-06-12 2009-03-25 株式会社ノエビア Condiment drink
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
JP2005312305A (en) * 2004-04-27 2005-11-10 Goodoo Kasei Kk Health agent
JP4713104B2 (en) * 2004-08-04 2011-06-29 ファイザー株式会社 A stable composition containing azithromycins as an active ingredient and having reduced bitterness
KR20080005552A (en) * 2005-04-22 2008-01-14 야이즈 스이산가가쿠 고교 가부시키가이샤 Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride produced by the process
JP4881268B2 (en) * 2006-09-25 2012-02-22 あすか製薬株式会社 Oral preparations with reduced bitterness

Also Published As

Publication number Publication date
CN101778626A (en) 2010-07-14
AR067887A1 (en) 2009-10-28
JP2010535757A (en) 2010-11-25
WO2009022674A1 (en) 2009-02-19
CN101778626B (en) 2014-05-07
KR20100051850A (en) 2010-05-18
JP2013177418A (en) 2013-09-09
JP5328789B2 (en) 2013-10-30
KR101551506B1 (en) 2015-09-08
TW200918060A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
MY157582A (en) Medical composition containing rebamipipe
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
BR112012011072A2 (en) n1-pyrazolospyrocetone acetyl coa carboxylase inhibitors
IN2012DN01233A (en)
EA201490521A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
MX350810B (en) 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication.
SG178952A1 (en) Chemical compounds
EA201492064A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX340147B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
GEP20135832B (en) Benzothiazines derivatives, preparation thereof, and their application as drugs
DE602007014206D1 (en) Novel serotonin reuptake inhibitor as a drug with peripheric system-restricted activity
GEP201606514B (en) Apoptosis inhibitors and usage thereof
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2009129208A3 (en) Compositions and methods of inducing endoplasmic reticulum stress reponse
EA201590790A1 (en) STABLE PHARMACEUTICAL COMPOSITION BASED ON PEG-INTERFERON ALPHA-2b
BR112012009311A2 (en) compound, pharmaceutical composition, and compound use